Authors
Artificial intelligence (AI) is transforming the biotechnology industry by enabling faster and more accurate analysis of complex biological data. The integration of AI in biotechnology has brought about numerous benefits, from accelerating drug discovery to advancing personalised medicine.
Here are some ways in which AI is transforming the biotechnology industry:
Accelerating Drug Discovery: The drug discovery process is long and expensive, often taking years and costing billions of dollars. AI has the potential to significantly reduce the time and cost involved in drug discovery by providing more efficient and accurate screening of molecules for drug development. AI algorithms can scan millions of molecules in a short period of time and predict their properties based on their molecular structures, which can help researchers identify promising drug candidates faster.
Precision Medicine: AI is also transforming the field of precision medicine, which focuses on tailoring treatments to individual patients based on their genetic makeup and other personal factors. AI algorithms can analyse large sets of patient data, including genetic data, medical records, and lifestyle factors, to identify patterns and develop personalised treatment plans. This can help doctors make more informed decisions about which treatments to prescribe, potentially leading to better health outcomes for patients.
Enhancing Clinical Trials: Clinical trials are a critical part of the drug development process, but they are also time-consuming and costly. AI is being used to improve the design and analysis of clinical trials, enabling researchers to identify the most promising patient cohorts, optimise dosing, and predict the likelihood of success. AI can also help to reduce the risk of negative side effects and improve patient safety by analysing adverse events during clinical trials.
Improving Drug Manufacturing: AI is transforming the way drugs are manufactured by enabling more efficient and cost-effective processes. AI algorithms can monitor manufacturing processes in real-time, predict when equipment is likely to fail, and optimise the process to reduce waste and increase efficiency. This can help to lower the cost of drug manufacturing and improve the quality of the drugs being produced.
Streamlining Medical Diagnostics: AI is also transforming the field of medical diagnostics by improving the accuracy and speed of medical imaging and analysis. AI algorithms can analyse medical images such as X-rays, CT scans, and MRI scans to detect potential disease markers, predict disease progression, and develop personalised treatment plans. This can help doctors make more informed decisions about which treatments to prescribe, potentially leading to better health outcomes for patients.
Enhancing Drug Repurposing: AI algorithms can be used to identify existing drugs that could be repurposed for new uses. This can help to accelerate drug development by leveraging the safety and efficacy data already available for these drugs.
Overall, AI is transforming the biotechnology industry by enabling faster, more efficient, and more accurate analysis of complex biological data. The integration of AI in biotechnology has the potential to revolutionize drug discovery, precision medicine, clinical trials, drug manufacturing, medical diagnostics, and drug repurposing. As AI continues to evolve, it is likely that we will see even more transformative applications of this technology in the biotechnology industry in the years to come.
---
The pace of innovation in technology is hard to imagine. We can look at how, each year, a new more advanced phone is available with features that twenty years ago might have been unimaginable. But more abstract terms like AI are less tangible and therefore harder to understand. Most of us are not aware of AI playing any significant role in our day-to-day existence. But all of this is set to change.
It usually takes us several hours to research and write our monthly blog. The first 500 words of this blog are Chat GPT’s answer to the question “How is AI transforming the biotechnology industry?” and were written in just a couple of seconds. This is a tangible example of how AI can speed up processes which hitherto required significant amount of human input. Overlaying that concept on an industry like biotechnology underscores our conviction that innovation in the biotechnology industry will continue to accelerate and technology will play an important role in that going forward.
Developing drugs has historically included an element of serendipity. Fleming discovered antibiotics by chance and many early and older drugs have their origins in nature discovered by trial and error through history. By handing drug discovery over to computers, some of the potential for incidental discovery may be lost.
First the development of high through-put screening (HTS) in the late 1990s and early 2000s and now, AI, have resulted in more targeted streamlined therapies with fewer unexpected side effects. However, the unwanted side effects, which led to previously approved drugs being described as “dirty” drugs, were not all negative and some laid the foundation for further biotech breakthroughs. For example, Viagra was discovered due to an unexpected (embarrassing but not altogether negative) side effect of a drug being tested for the treatment of hypertension and cardiovascular disease! It is also possible that by having fewer attempts to hit the target, a whole programme could be closed down due to toxicity in its product, when a closely related product that was filtered out of the process by AI may not have had the same toxicity. So, while more targeted drugs may accelerate the pace of drug development, it will be impossible to quantify what potential opportunities for breakthroughs may be missed due to the highly targeted, streamlined nature of the process.
As biotech investors, we are not specifically targeting AI from an investment perspective. AI is already playing a role behind the scenes in some of the big biotech names we own, but in the main, AI is being advanced by companies in the tech space. However, we are optimistic about the impact that AI will have on improving the speed and success rate of biotech innovation and drug discovery. We expect that to underpin the positive momentum in the fundamentals driving the biotech industry into the future.
Important information
This communication is marketing material. The views and opinions contained herein are those of the named author(s) on this page, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds.
This document is intended to be for information purposes only and it is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The material is not intended to provide, and should not be relied on for, accounting, legal or tax advice, or investment recommendations. Information herein is believed to be reliable but Schroder Investment Management Ltd (Schroders) does not warrant its completeness or accuracy.
The data has been sourced by Schroders and should be independently verified before further publication or use. No responsibility can be accepted for error of fact or opinion. This does not exclude or restrict any duty or liability that Schroders has to its customers under the Financial Services and Markets Act 2000 (as amended from time to time) or any other regulatory system. Reliance should not be placed on the views and information in the document when taking individual investment and/or strategic decisions.
Past Performance is not a guide to future performance. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested. Exchange rate changes may cause the value of any overseas investments to rise or fall.
Any sectors, securities, regions or countries shown above are for illustrative purposes only and are not to be considered a recommendation to buy or sell.
The forecasts included should not be relied upon, are not guaranteed and are provided only as at the date of issue. Our forecasts are based on our own assumptions which may change. Forecasts and assumptions may be affected by external economic or other factors.
Issued by Schroder Unit Trusts Limited, 1 London Wall Place, London EC2Y 5AU. Registered Number 4191730 England. Authorised and regulated by the Financial Conduct Authority.
Authors
Topics